TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company that is revolutionizing cancer treatment. With a scientific approach and a focus on gamma delta T cells, TC BioPharm is developing advanced allogeneic CAR-T cell therapy products that have great potential in fighting cancer. In addition to their CAR-T therapies, TC BioPharm is also working on gamma delta T cell therapies to combat infectious diseases.

Since its establishment in 2014, TC BioPharm has rapidly grown, expanding into five global locations and employing over 100 professionals. Their integrated model drives the development of safer and more affordable CAR-T products, with the goal of targeting a wider range of cancers and saving more lives. By taking products from preclinical testing to the clinical stage, TC BioPharm is dedicated to developing innovative cell-based therapies that improve patient health and enhance their quality of life.

With partnerships with leading organizations such as bluebird bio and Trinity College Dublin, TC BioPharm is at the forefront of cutting-edge research and development. Join them in their mission to revolutionize cancer treatment by exploring career opportunities or connecting with them today